观察铜绿假单胞菌甘露糖敏感血凝素（PA-MSHA）对根治性膀胱切除术（RC）患者预后及淋巴漏发生率的影响。 选取2013年至2013年兰州大学第二医院接受根治性膀胱切除术（RC）的患者129例。 2022 人参加了这项研究。他们被分为 43 名接受 PA-MSHA 治疗的患者和 86 名对照组患者。应用治疗加权逆概率（IPTW）来减少潜在的选择偏差。采用Kaplan-Meier法和Cox回归分析分析PA-MSHA对患者生存率和术后淋巴漏发生率的影响。PA-MSHA组表现出改善的总生存期（OS）和癌症特异性生存期（CSS） ）与对照组相比的比率。 PA-MSHA 组的 3 年和 5 年总生存 (OS) 率分别为 69.1% 和 53.2%，而对照组为 55.6% 和 45.3%（Log-rank=3.218，P=0.072） ）。 PA-MSHA 组的 3 年和 5 年癌症特异性生存 (CSS) 率分别为 73.3% 和 56.5%，而对照组为 58.0% 和 47.3%（Log-rank=3.218，P =0.072）。此外，PA-MSHA 组的 3 年和 5 年无进展生存 (PFS) 率分别为 74.4% 和 56.8%，而对照组为 57.1% 和 52.2%（Log-rank=2.016） ，P=0.156）。多因素Cox回归分析显示淋巴结转移和远处转移是患者不良预后因素，而使用PA-MSHA可以改善患者的OS（HR：0.547，95%CI：0.304-0.983，P=0.044）、PFS （HR：0.469，95%CI：0.229-0.959，P=0.038）和CSS（HR：0.484，95%CI：0.257-0.908，P=0.024）。 IPTW 调整后的队列中观察到了相同的趋势。尽管术后淋巴漏发生率[18.6%（8/35）比15.1%（84.9%），P=0.613]和盆腔引流量[470（440）ml比462.5（430）ml没有显着差异。 ml，P=0.814]PA-MSHA组与对照组相比，PA-MSHA可缩短引流管中位保留时间（7.0 d vs 9.0 d）（P=0.021）。PA-MSHA可改善膀胱癌根治术OS、PFS、CSS，缩短盆腔引流管保留时间。版权所有 © 2024 张、裴、任、石、陆、水、马、张、丁、张、田、王。

To observe the effect of Pseudomonas aeruginosa mannose-sensitive hemagglutinin (PA-MSHA) on the prognosis and the incidence of lymphatic leakage in patients undergoing radical cystectomy (RC).A total of 129 patients who underwent RC in Lanzhou University Second Hospital from 2013 to 2022 were enrolled in this study. They were divided into 43 patients treated with PA-MSHA and 86 patients in the control group. Inverse probability of treatment weighting (IPTW) was applied to reduce potential selection bias. Kaplan-Meier method and Cox regression analysis were used to analyze the effect of PA-MSHA on the survival of patients and the incidence of postoperative lymphatic leakage.The PA-MSHA group exhibited improved overall survival (OS) and cancer-specific survival (CSS) rates compared to the control group. The 3-year and 5-year overall survival (OS) rates for the PA-MSHA group were 69.1% and 53.2%, respectively, compared to 55.6% and 45.3% for the control group (Log-rank=3.218, P=0.072). The 3-year and 5-year cancer-specific survival (CSS) rates for the PA-MSHA group were 73.3% and 56.5%, respectively, compared to 58.0% and 47.3% for the control group (Log-rank=3.218, P=0.072). Additionally, the 3-year and 5-year progression-free survival (PFS) rates for the PA-MSHA group were 74.4% and 56.8%, respectively, compared to 57.1% and 52.2% for the control group (Log-rank=2.016, P=0.156). Multivariate Cox regression analysis indicates that lymph node metastasis and distant metastasis are poor prognostic factors for patients, while the use of PA-MSHA can improve patients' OS (HR: 0.547, 95%CI: 0.304-0.983, P=0.044), PFS (HR: 0.469, 95%CI: 0.229-0.959, P=0.038) and CSS (HR: 0.484, 95%CI: 0.257-0.908, P=0.024). The same trend was observed in the cohort After IPTW adjustment. Although there was no significant difference in the incidence of postoperative lymphatic leakage [18.6% (8/35) vs. 15.1% (84.9%), P=0.613] and pelvic drainage volume [470 (440) ml vs. 462.5 (430) ml, P=0.814] between PA-MSHA group and control group, PA-MSHA could shorten the median retention time of drainage tube (7.0 d vs 9.0 d) (P=0.021).PA-MSHA may improve radical cystectomy in patients with OS, PFS, and CSS, shorten the pelvic drainage tube retention time.Copyright © 2024 Zhang, Pei, Ren, Shi, Lu, Shui, Ma, Zhang, Ding, Zhang, Tian and Wang.